
Introduction Extended depth-of-focus (EDOF) intraocular lenses (IOL) offer a new approach to improve depth perception after cataract surgery but may come with potential drawbacks. The use of EDOF IOLs requires thorough evaluation of options and performance as well as careful consideration of the recipients’ working requirements and existing regulations. There may be a high risk of a mismatch. Methods The principles of EDOF IOLs will be reviewed, significant differences from classic, approved, monofocal IOL designs outlined, and a specific group of patients identified: pilots. In this context, a case in which EDOF IOLs were implanted will be discussed, with emphasis on the consequences. Results Although EDOF IOLs have become a common choice for many patients and perform well, not all current EDOF IOLs perform in compliance with the rules and regulations for aviation. Disparities and misconceptions exist as to whether or not EDOF IOLs can be considered acceptable in aviation. Depending on applicable rules and regulations, there are globally significant differences. Even when individual performance may allow for continuation of flying duties, the regulations of some regions are not yet generally permissive, leading to undesirable and unnecessary negative sequelae. Discussion In contrast to classic monofocal IOLs, EDOF IOLs cannot be presumed to be generally accepted by all authorities engaged in global aviation. As EDOF IOL designs vary, their effects on contrast sensitivity, halo, and glare may also differ considerably. Therefore, prior surgery and prior to opting for an EDOF IOL, both the ophthalmic surgeon and the pilot should obtain detailed knowledge of the matter before decision making and, if unsure, consult the AME as well as the relevant aviation authorities if there are any questions. Conclusion EDOF IOLs are not yet generally accepted for aviation. Although the enhanced performance of EDOF IOLs might be tempting, the postoperative results and their acceptability might vary considerably, currently necessitating a very careful approach.
Purpose To report a familial case series of anterior lentiplane with congenital cataract-microcornea syndrome (CCMC) and describe the imaging characteristics of anterior lentiplane using anterior segment optical coherence tomography (AS-OCT). Methods This study is comprised of a description of a clinical case series, an investigation into the radius of anterior lens curvature (RAL), and a review of the relevant literature. Results A 34-year-old woman was referred to the hospital for cataract and glaucoma evaluation. Eye examination revealed a posterior polar cataract, microcornea, and goniodysgenesis. AS-OCT demonstrated a markedly flat anterior lens surface (anterior lentiplane) and an increased central corneal thickness (CCT) in both eyes. A diagnosis of anterior lentiplane with CCMC and secondary glaucoma was made. Cataract surgery was performed on both eyes, and the glaucoma was controlled with medications. Her 15-year-old son showed similar bilateral microcornea with goniodysgenesis on eye screening. AS-OCT also revealed anterior lentiplane, increased CCT, and early cataract in the posterior lens of both eyes. Bilateral CCMC with anterior lentiplane was diagnosed. The RAL was calculated from AS-OCT images using a geometric approach (16.41 mm OD and 20.99 mm OS for the mother, and 37.66 mm OD and 38.30 mm OS for the son). Conclusions To the best of the authors’ knowledge, this is the first clinically documented report of anterior lentiplane in cataract-microcornea syndrome as a familial case, and the first study to provide a quantitative description of its imaging characteristics using AS-OCT.
The expiration of patents for ranibizumab and 2-mg aflibercept has enabled the introduction of several anti–vascular endothelial growth factor (anti-VEGF) biosimilars into ophthalmic practice. Simultaneously, recent changes in the French regulatory framework, particularly those introduced by the 2026 Social Security Financing Act, will expand pharmacist-led substitution of biological medicines as of September 1, 2026. These changes raise important questions for ophthalmologists regarding efficacy, safety, immunogenicity, switching strategies, as well as traceability, liability, and patient information. This review summarizes the scientific principles underlying biosimilar development and regulatory approval, highlighting the analytical, preclinical, and clinical requirements necessary to establish biosimilarity. Current evidence regarding ranibizumab and 2-mg aflibercept biosimilars is reviewed, including pivotal clinical trials, switching studies, and recent meta-analyses, all of which support efficacy, safety, and immunogenicity profiles comparable to those of their reference products over the short and medium term. Nevertheless, several ophthalmology-specific considerations deserve particular attention, including physician-administered intravitreal injections, differences in drug presentation, the long-term management of predominantly elderly patients, and the rarity of intraocular inflammatory events. Furthermore, biosimilars are being introduced into a rapidly evolving therapeutic landscape characterized by the emergence of second-generation anti-VEGF agents designed to reduce treatment burden. Biosimilars therefore represent an important opportunity to enhance the sustainability of healthcare systems. Their integration into routine clinical practice, however, should rely on a gradual, individualized approach supported by robust pharmacovigilance.
Purpose To describe real-world experience after adding preservative-free hydrocortisone 0.335% to manage ocular surface inflammation in patients with dry eye disease (DED) who required combined therapy. Methods This retrospective, multicenter, international case series evaluated 27 patients diagnosed with DED that was poorly controlled on a regimen of ocular lubricants or multimodal treatment and were prescribed topical preservative-free hydrocortisone 0.335% for combination therapy. Similarity and quality of data collection were the main inclusion criteria for inclusion in the study. Data are reported as mean, standard deviation and range for quantitative variables at baseline and the last follow-up visit after initiating low-dose hydrocortisone therapy. Intergroup data were compared using the Kolmogorov–Smirnov test followed by the nonparametric Mann-Whitney test. P < 0.05 was considered statistically significant. Results The severity of DED ranged from mild to severe, with cases that included mixed etiology and DED related to chronic graft versus host disease. Mean intraocular pressure (IOP) was 14.77 ± 2.48 mmHg at baseline and 14.75 ± 2.52 mmHg at 2 weeks after initiating low-dose hydrocortisone therapy. There were no cases of an IOP spike during treatment with the preservative-free low-dose hydrocortisone. The mean ocular surface disease index (OSDI) score decreased statistically significantly from 27.44 ± 15.80 at baseline to 19.10 ± 10.84 at 2 weeks after initiating low-dose hydrocortisone therapy (P < 0.05). There was a clinically significant improvement in these parameters as indicated by Schirmer tests I and II, grading of conjunctival hyperemia and corneal staining. After addition of low-dose preservative-free hydrocortisone, treatment was successful in all cases, with 18 (66.7%) defined as resolved and 9 (33.3%) defined as stable. None of patients were intolerant to the preservative-free low-dose corticosteroid formulation. Conclusion In patients with DED recalcitrant to medical therapy, addition of low-dose, preservative-free hydrocortisone in combination therapy with ocular lubricants improved the signs and symptoms of mild to severe cases without inciting adverse events such as an IOP spike or ocular infections. Treatment was considered successful in all cases.